Trial Profile
Study phase II to determinate the efficacy of sunitinib in patients with renal cells carcinoma metastasic or locally avanced in patients not candidates to curative previous nefrectomy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Oct 2015
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 05 Mar 2010 Results of an analysis which aims to identify genetic markers of response and adverse effects of sunitinib were presented at ASCO 2010 Genitourinary Cancers Symposium.
- 19 May 2008 New trial record.